the obvious reason: their big-spending pharmaceutical advertisers would drop them like hot potatoes.
.
.
.
"it's a very exciting time," klugman said. "this is exactly where we would like prenatal diagnosis to go -- to be able to act on it."
.
erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
.
may 16, 2018
.